Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Gastric Adenocarcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Gastric Cancer (780)

Gastroesophageal Junction Adenocarcinoma (185)

Gastroesophageal Cancer (41)

Gastric Cancer (780)

Gastroesophageal Junction Adenocarcinoma (185)

Gastroesophageal Cancer (41)

›

No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
HER-2 overexpression	Gastric Adenocarcinoma	HER-2 overexpression	Gastric Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 overexpression	Gastric Adenocarcinoma	HER-2 overexpression	Gastric Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
HER-2 overexpression	Gastric Adenocarcinoma	HER-2 overexpression	Gastric Adenocarcinoma	pembrolizumab + trastuzumab Sensitive: A2 - Guideline pembrolizumab + trastuzumab Sensitive : A2	pembrolizumab + trastuzumab Sensitive: A2 - Guideline pembrolizumab + trastuzumab Sensitive : A2
MET expression	Gastric Adenocarcinoma	MET expression	Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification	Gastric Adenocarcinoma	MET amplification	Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
PD-L1 underexpression	Gastric Adenocarcinoma	PD-L1 underexpression	Gastric Adenocarcinoma	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B
HER-2 negative + PD-L1 expression	Gastric Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastric Adenocarcinoma	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
HER-2 underexpression	Gastric Adenocarcinoma	HER-2 underexpression	Gastric Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 positive	Gastric Adenocarcinoma	HER-2 positive	Gastric Adenocarcinoma	pembrolizumab + margetuximab-cmkb Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab-cmkb Sensitive : C2	pembrolizumab + margetuximab-cmkb Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab-cmkb Sensitive : C2